Immunoglobulins are antibodies naturally produced by the body’s immune system to fight infections and diseases. When the body has a deficiency, external administration becomes necessary through immunoglobulin replacement therapy (IgRT). This can be delivered intravenously (IVIg) or subcutaneously (SCIg), depending on the indication and severity. IVIg is manufactured from human plasma and contains a broad spectrum of antibodies, making it effective for treating a growing range of disorders.

 Intravenous Immunoglobulin Market Overview

The global intravenous immunoglobulin (IVIg) market was valued at US$ 11,206.54 million in 2021 and is projected to reach US$ 18,672.55 million by 2028, expanding at a CAGR of 7.6% from 2022 to 2028. IVIg therapy continues to gain traction as a critical treatment option for various immunologic, hematologic, and neurologic conditions.

Market Drivers

The primary factors fueling market growth include the rising prevalence of immunodeficiency diseases and the increasing geriatric population worldwide. According to the National Institute of Allergy and Infectious Diseases (NIAID), over 200 different types of primary immune deficiency diseases (PIDDs) affect about 500,000 people in the US. Immune Thrombocytopenia (ITP), an autoimmune bleeding disorder, records around 200,000 cases annually worldwide.

Market Segmentation and Insights

By Type

The market segments into IgG, IgM, IgA, IgE, and IgD. The IgG segment dominated with the largest market share of 29% in 2021. Its wide application across multiple disorders positions it as the leading type, with strong growth expected to continue.

For detailed data analysis, download the free sample: https://www.theinsightpartners.com/sample/TIPRE00004079

By Application

Key applications include hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.

The immunodeficiency diseases segment held the largest share in 2021 and is anticipated to register the fastest CAGR of 8.2% during the forecast period, driven by rising disease prevalence and increasing FDA approvals for IVIg products.

By Distribution Channel

The market divides into hospital pharmacy, retail pharmacy, and others. Hospital pharmacy accounted for the largest share of 55.5% in 2021. However, the retail pharmacy segment is expected to grow at the fastest rate due to pharmacy expansions and shifting consumer preferences toward organized retail.

By End User

End users include hospitals, specialty clinics, and others. Hospitals held the largest share in 2021, while specialty clinics are projected to witness the fastest growth at a CAGR of 8.2%, benefiting from advances in delivering quick and accurate IgRT.

Regional Analysis

North America dominated the market with a 38.6% share in 2021. The United States is projected to grow at a CAGR of 7.9%.

Asia Pacific is poised to be the fastest-growing region, expected to register a CAGR of 8.1% over the forecast period, driven by improving healthcare infrastructure, rising awareness, and growing patient pools.

Key Developments

Market players actively pursue organic strategies such as product approvals:

• In March 2022, ADMA Biologics, Inc. received FDA approval to extend the expiration dating for ASCENIV and BIVIGAM from 24 to 36 months.
• In June 2021, Octapharma secured EU approval for octagam 10% as an immunomodulatory therapy for adults with dermatomyositis.
• In April 2021, ADMA Biologics gained FDA approval for an expanded manufacturing process using a 4,400-liter plasma pool.
• In February 2020, CSL Behring received orphan-drug designation for Privigen in treating Systemic Sclerosis.

These developments strengthen supply chains, expand indications, and enhance product availability.

Competitive Landscape

Leading companies in the intravenous immunoglobulin market include: Takeda Pharmaceutical Company Limited, Grifols S.A., Pfizer Inc., ADMA Biologics Inc., Bio Products Laboratory Ltd., Shanghai RAAS, Octapharma AG, Kedrion S.p.A, CSL Behring (CSL Limited), and Prothya Biosolutions B.V.

About The Insight Partners

The Insight Partners delivers market intelligence and consulting services to help clients make informed decisions. The firm covers industries such as Aerospace and Defense, Automotive and Transportation, Semiconductor and Electronics, Biotechnology, Healthcare IT, Manufacturing, Medical Devices, Technology, Media, and Chemicals and Materials.

Contact Us

Email: sales@theinsightpartners.com

Website: www.theinsightpartners.com

Phone: +1-646-491-9876